EM performance and hippocampal volume (HV) were characterized in patients with mild AD based on <i>APOE</i>-ε4 carrier status (<i>APOE</i>-ε4 carriers versus non-carriers) and <i>FGF1</i> single nucleotide polymorphism (<i>FGF1-</i>rs34011-GG versus <i>FGF1-</i>rs34011-A-allele carriers).
Our data suggest that inhibition of expression or release of aFGF could have therapeutic potential by inhibiting inflammation in neurodegenerative diseases such as Alzheimer disease where many neuroinflammatory molecules are prominently expressed.
Immunohistochemical examination of postmortem brain tissue of Alzheimer's disease revealed that acidic fibroblast growth factor (aFGF) was specifically expressed in a subpopulation of reactive astrocytes which were congregated at the margin of the senile plaque.